AB
BTAI icon

Amalgamated Bank’s BioXcel Therapeutics BTAI Stock Holding History

Amalgamated Bank’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44
Closed -$2K – 3023
2024
Q1 		$2K Sell
44
-129
-75% -$6.15K ﹤0.01% 2872
2023
Q4 		$8K Sell
173
-13
-7% -$723 ﹤0.01% 2885
2023
Q3 		$8K Hold
186
– – ﹤0.01% 2926
2023
Q2 		$20K Buy
186
+60
+48% +$20K ﹤0.01% 2740
2023
Q1 		$38K Sell
126
-20
-14% -$8.54K ﹤0.01% 2411
2022
Q4 		$50K Hold
146
– – ﹤0.01% 2413
2022
Q3 		$28K Hold
146
– – ﹤0.01% 2707
2022
Q2 		$31K Sell
146
-30
-17% -$6.31K ﹤0.01% 2702
2022
Q1 		$59K Buy
+176
New +$51K ﹤0.01% 2392

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Amalgamated Bank's BTAI Position: Q2 2024 in Review

Amalgamated Bank sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 44 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in BTAI in Q1 2022 and held it in 9 quarters. The position peaked at $59K in Q1 2022. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Amalgamated Bank reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Amalgamated Bank sold 44 BioXcel Therapeutics shares in Q2 2024, an estimated $2K.
  • Amalgamated Bank first reported a position in BioXcel Therapeutics in Q1 2022 and held it in 9 quarters.
  • Amalgamated Bank's BioXcel Therapeutics position peaked at $59K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Amalgamated Bank's 13F filing for Q2 2024, filed 12 Aug 2024.